Ajax Therapeutics, Inc. announced that it will issue 44,854,252 series C preferred shares at issue price of $2.11797 per share for the gross proceeds $94,999,960.10844 in funding on April 26, 2024. The shares are convertible, and redeemable. The shares will be convertible in common shares at a price of $2.11797 per share.

The round will be raised at post money valuation of $154,000,549. The company will issue securities pursuant to exemption provided under Regulation D.